Johnson & Johnson - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of Johnson & Johnson Company

Johnson & Johnson is an American multinational corporation specializing in pharmaceuticals, biotechnology, and medical technologies, headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange (NYSE:JNJ). Its common stock is part of the Dow Jones Industrial Average, and the company is ranked No. 42 on the 2024 Fortune 500 list of the largest corporations in the United States. In 2024, it was ranked 45th on the Forbes Global 2000 list. Johnson & Johnson employs approximately 138,000 individuals globally, led by its current chairman and CEO, Joaquin Duato.

Founded in 1886 by three brothers—Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson—the company initially focused on selling ready-to-use sterile surgical dressings. In 2023, the firm spun off its consumer healthcare business segment into a new publicly traded entity, Kenvue, allowing it to concentrate solely on the development and manufacturing of pharmaceutical prescription drugs and medical device technologies.

Johnson & Johnson is recognized as one of the most valuable companies worldwide and is one of only two U.S.-based corporations possessing a prime credit rating of AAA.

Johnson & Johnson Info



Ticker SymbolJNJ

Company nameJohnson & Johnson

IPO dateSep 25, 1944

CEOMr. Joaquin Boix Duato

Number of employees138100

Security typeOrdinary Share

Fiscal year-endSep 25

AddressOne Johnson & Johnson Plaza

CityNEW BRUNSWICK

Stock exchangeNYSE Consolidated

CountryUnited States of America

Postal code08933

Phone17325242455

Websitehttps://www.jnj.com/

Ticker SymbolJNJ

IPO dateSep 25, 1944

CEOMr. Joaquin Boix Duato

Company Executives of Johnson & Johnson



Name

Name/Position

Position

Shareholding

Change

Mr. Joaquin Boix Duato

Chairman of the Board, Chief Executive Officer

276.91K

--

Ms. Jennifer L. Taubert

Executive Vice President, Worldwide Chairman, Innovative Medicine

178.01K

--

Ms. Kathryn E. Wengel

Executive Vice President, Chief Technology Officer and Risk Officer

94.62K

+14.54%

Mr. Joseph J. Wolk

Chief Financial Officer, Executive Vice President

84.95K

--

Ms. Vanessa Broadhurst

Executive Vice President - Global Corporate Affairs

23.59K

+18.96%

Ms. Kristen Mulholland

Chief Human Resources Officer, Executive Vice President

14.12K

+20.79%

Ms. Elizabeth (Liz) Forminard

Executive Vice President, Chief Legal Officer

12.85K

+17.90%

Prof. Dr. John C. Reed, M.D., Ph.D.

Executive Vice President - Innovative Medicine, Research and Development

10.66K

--

Mr. Hubert Joly

Independent Director

5.00K

--

Ms. Marillyn A. Hewson

Lead Independent Director

3.00K

--

Name

Name/Position

Position

Shareholding

Change

Mr. Joaquin Boix Duato

Chairman of the Board, Chief Executive Officer

276.91K

--

Ms. Jennifer L. Taubert

Executive Vice President, Worldwide Chairman, Innovative Medicine

178.01K

--

Ms. Kathryn E. Wengel

Executive Vice President, Chief Technology Officer and Risk Officer

94.62K

+14.54%

Mr. Joseph J. Wolk

Chief Financial Officer, Executive Vice President

84.95K

--

Ms. Vanessa Broadhurst

Executive Vice President - Global Corporate Affairs

23.59K

+18.96%

Ms. Kristen Mulholland

Chief Human Resources Officer, Executive Vice President

14.12K

+20.79%

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

Oncology-DARZALEX

3.54B

14.91%

Immunology-STELARA

1.65B

6.96%

Cardiovascular-ELECTROPHYSIOLOGY

1.47B

6.18%

Surgery-General

1.39B

5.86%

Immunology-TREMFYA

1.19B

5.00%

Other

14.51B

61.10%

By RegionUSD

Name

Revenue

Proportion

United States

13.54B

57.04%

Europe

5.39B

22.69%

Asia-Pacific, Africa

3.61B

15.19%

Western Hemisphere, excluding U.S.

1.21B

5.08%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Oncology-DARZALEX

3.54B

14.91%

Immunology-STELARA

1.65B

6.96%

Cardiovascular-ELECTROPHYSIOLOGY

1.47B

6.18%

Surgery-General

1.39B

5.86%

Immunology-TREMFYA

1.19B

5.00%

Other

14.51B

61.10%

Shareholding Stats

Updated: Tue, May 13

Shareholders

Shareholder Types

Shareholders

Proportion

The Vanguard Group, Inc.

9.78%

State Street Investment Management (US)

5.51%

BlackRock Institutional Trust Company, N.A.

5.39%

Geode Capital Management, L.L.C.

2.52%

JP Morgan Asset Management

1.52%

Other

75.29%

Shareholders

Proportion

The Vanguard Group, Inc.

9.78%

State Street Investment Management (US)

5.51%

BlackRock Institutional Trust Company, N.A.

5.39%

Geode Capital Management, L.L.C.

2.52%

JP Morgan Asset Management

1.52%

Other

75.29%

Shareholder Types

Shareholders

Proportion

Investment Advisor

38.83%

Investment Advisor/Hedge Fund

24.12%

Research Firm

3.00%

Pension Fund

2.38%

Bank and Trust

2.20%

Insurance Company

1.62%

Sovereign Wealth Fund

1.42%

Hedge Fund

0.69%

Family Office

0.09%

Other

25.65%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

5871

1.79B

74.36%

+2.90M

2025Q2

5920

1.78B

73.89%

-7.65M

2025Q1

6002

1.80B

74.62%

+4.60M

2024Q4

5953

1.78B

74.14%

+8.28M

2024Q3

5699

1.77B

73.47%

+2.69M

2024Q2

5691

1.75B

72.75%

+9.12M

2024Q1

5685

1.73B

71.58%

-6.08M

2023Q4

5686

1.72B

71.40%

-7.80M

2023Q3

5524

1.72B

71.21%

-159.24M

2023Q2

5528

1.87B

71.81%

+6.27M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

236.03M

9.8%

+3.04M

+1.31%

Jun 30, 2025

State Street Investment Management (US)

132.80M

5.51%

-992.45K

-0.74%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

129.76M

5.39%

+619.12K

+0.48%

Jun 30, 2025

Geode Capital Management, L.L.C.

60.61M

2.52%

+1.23M

+2.06%

Jun 30, 2025

JP Morgan Asset Management

36.71M

1.52%

+1.46M

+4.13%

Jun 30, 2025

State Farm Insurance Companies

34.37M

1.43%

--

Jun 30, 2025

Norges Bank Investment Management (NBIM)

31.93M

1.33%

+1.57M

+5.18%

Jun 30, 2025

Morgan Stanley Smith Barney LLC

25.30M

1.05%

+1.23M

+5.13%

Jun 30, 2025

Wellington Management Company, LLP

24.88M

1.03%

+2.23M

+9.85%

Jun 30, 2025

BlackRock Asset Management Ireland Limited

19.85M

0.82%

+148.42K

+0.75%

Jun 30, 2025

Related ETFs



Updated: Thu, Nov 6

Name

Proportion

iShares U.S. Pharmaceuticals ETF

23.26%

iShares ESG Aware MSCI USA Value ETF

12.37%

Health Care Select Sector SPDR Fund

8.85%

Proshares Ultra Health Care

8.83%

iShares U.S. Healthcare ETF

8.5%

FT Vest DJIA Dogs 10 Target Income ETF

8.21%

JPMorgan Healthcare Leaders ETF

7.97%

Fidelity MSCI Health Care Index ETF

7.7%

Franklin Income Focus ETF

7.69%

First Trust NASDAQ Pharmaceuticals ETF

7.68%

iShares U.S. Pharmaceuticals ETF

Proportion23.26%

iShares ESG Aware MSCI USA Value ETF

Proportion12.37%

Health Care Select Sector SPDR Fund

Proportion8.85%

Proshares Ultra Health Care

Proportion8.83%

iShares U.S. Healthcare ETF

Proportion8.5%

FT Vest DJIA Dogs 10 Target Income ETF

Proportion8.21%

JPMorgan Healthcare Leaders ETF

Proportion7.97%

Fidelity MSCI Health Care Index ETF

Proportion7.7%

Franklin Income Focus ETF

Proportion7.69%

First Trust NASDAQ Pharmaceuticals ETF

Proportion7.68%

Dividend



A total of 56.79B USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

Jan 02, 2025

JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Mar 04, 2025 going ex on Feb 18, 2025

Feb 18, 2025

Mar 04, 2025

Feb 18, 2025

Oct 15, 2024

JNJ.NB Final Cash Dividend of gross USD 1.24 paid on Dec 10, 2024 going ex on Nov 26, 2024

Nov 26, 2024

Dec 10, 2024

Nov 26, 2024

Jul 17, 2024

JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Sep 10, 2024 going ex on Aug 27, 2024

Aug 27, 2024

Sep 10, 2024

Aug 27, 2024

Apr 16, 2024

JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Jun 04, 2024 going ex on May 20, 2024

May 21, 2024

Jun 04, 2024

May 20, 2024

Jan 02, 2024

JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Mar 05, 2024 going ex on Feb 16, 2024

Feb 20, 2024

Mar 05, 2024

Feb 16, 2024

Oct 19, 2023

JNJ.NB Final Cash Dividend of gross USD 1.19 paid on Dec 05, 2023 going ex on Nov 20, 2023

Nov 21, 2023

Dec 05, 2023

Nov 20, 2023

Jul 20, 2023

JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Sep 07, 2023 going ex on Aug 25, 2023

Aug 28, 2023

Sep 07, 2023

Aug 25, 2023

Apr 18, 2023

JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Jun 06, 2023 going ex on May 22, 2023

May 23, 2023

Jun 06, 2023

May 22, 2023

Jan 03, 2023

JNJ.NB Interim Cash Dividend of gross USD 1.13 paid on Mar 07, 2023 going ex on Feb 17, 2023

Feb 21, 2023

Mar 07, 2023

Feb 17, 2023

Oct 18, 2022

JNJ.NB Final Cash Dividend of gross USD 1.13 paid on Dec 06, 2022 going ex on Nov 21, 2022

Nov 22, 2022

Dec 06, 2022

Nov 21, 2022

Stock Split



Date

Type

Ratio

No Data

Date

Type

Ratio

No Data